AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

IODIXANOL

11 registrations across 3 African markets— 8 active

Markets with IODIXANOL

Recent registrations

Brand / ProductMarketHolderStatusExpires
VISIPAQUE
Solution injectable / 320 mg/ml
🇹🇳TunisiaGE HEALTHCARE AS NORVEGEexpiredMar 2012
VISIPAQUE
Solution injectable / 320 mg/ml
🇹🇳TunisiaGE HEALTHCARE AS NORVEGEexpiredMar 2012
VISIPAQUE
Solution injectable / 320 mg/ml
🇹🇳TunisiaGE HEALTHCARE AS NORVEGEexpiredMar 2012
VISIPAQUE 320 mg I/ml 500 ml (POLYPROPYLENE BOTTLE)🇿🇦South AfricaGE Healthcare (Pty) LtdactiveJan 1900
VISIPAQUE 270 mg I/ml 20 ml🇿🇦South AfricaGE Healthcare (Pty) LtdactiveJan 1900
VISIPAQUE 270 mg I/ml 50 ml🇿🇦South AfricaGE Healthcare (Pty) LtdactiveJan 1900
VISIPAQUE 320 mg I/ml 20 ml🇿🇦South AfricaGE Healthcare (Pty) LtdactiveJan 1900
VISIPAQUE 320 mg I/ml 50 ml🇿🇦South AfricaGE Healthcare (Pty) LtdactiveJan 1900
VISIPAQUE 320 mg I/ml 100 ml🇿🇦South AfricaGE Healthcare (Pty) LtdactiveJan 1900
VISIPAQUE 320 mg I/ml 200 ml (POLYPROPYLENE BOTTLE)🇿🇦South AfricaGE Healthcare (Pty) LtdactiveJan 1900
Cardiolek-320
Injection
🇹🇿TanzaniaUNIQUE PHARMACEUTICAL LABORATORIES (A Div. of J. B. Chemicals & Pharmaceuticals Ltd)active

IODIXANOL in Africa — Regulatory Overview

IODIXANOL is registered across 3 African markets with 11 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including South Africa, Tunisia, Tanzania. AfricaRegulatory refreshes this data daily from official government sources.

Of the 11 registrations, 8 (73%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.